Lipiodol Prior to FET (LIFE)

Launched by MỸ ĐỨC HOSPITAL · Aug 18, 2024

Keywords

ClinConnect Summary

The LIFE trial is studying a treatment called Lipiodol® to see if it can improve pregnancy rates for women undergoing In Vitro Fertilization (IVF) or Intracytoplasmic Sperm Injection (ICSI). Lipiodol® is a substance that might help the lining of the uterus (the endometrium) work better, which could make it easier for a fertilized embryo to implant and grow. This trial aims to find out if using Lipiodol® before transferring frozen embryos can help women with unexplained infertility achieve successful pregnancies.

To be eligible for this study, participants must be women who are planning to undergo IVF or ICSI and have decided to freeze their embryos for later transfer. They should also be healthy enough based on specific blood tests and must agree to transfer up to two frozen embryos. However, certain medical conditions, such as allergies to iodine or previous surgeries on the fallopian tubes, may exclude someone from participating. If you join this study, you’ll be closely monitored and will receive detailed information about the Lipiodol® procedure. This trial is not yet recruiting participants, but it offers a chance to contribute to important research that could help many women facing fertility challenges.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Women undergoing IVF/ICSI
• • Having indications for freeze-all (day-3 or day-5)
• • Agree to have ≤ 2 frozen embryos transferred
• • TSH \< 2.5 mIU/mL
• • Permanent resident in Viet Nam
• • Agree to participate in the study by signing the inform consent
• Exclusion Criteria:
• • Iodine allergy
• • History of salpingectomy or tubal ligation
• • History of using Lipiodol® within 6 months prior, starting from the screening time
• • At high risk of having Fallopian tube disorders (history of Chlamydia infection, history of pelvic inflammatory diseases, current endometriosis)
• • Having evidence of Fallopian tube disorders on Hysterosalpingo - Foam Sonography (HyFoSy), hysterosalpingography (HSG), ultrasonography or laparoscopy
• • Having untreated intrauterine lesions such as endometrial polyps, submucosal fibroids, etc which affect the outcome of IVF treatment
• • Have a history of thyroid disease or being treated for thyroid disease
• • Undergoing curettage within 30 days before performing HSG technique
• • Patients having embryos from oocyte donation or in vitro maturation (IVM) cycles
• • Unable or unwilling to attend Lipiodol® procedure
• • Participating in another interventional study at the same time